Etelcalcetide manufacturers
- Etelcalcetide
-
- $0.00 / 1Box
-
2025-08-20
- CAS:1262780-97-1
- Min. Order: 1Box
- Purity: 99.99%
- Supply Ability: 10 Boxes
- Etelcalcetide
-
- $75.00 / 1kg
-
2025-06-03
- CAS:1262780-97-1
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
- Etelcalcetide
-
- $15.00 / 1KG
-
2021-07-13
- CAS:1262780-97-1
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Etelcalcetide Basic information |
| Product Name: | Etelcalcetide | | Synonyms: | Etelcalcetide;D-Argininamide, N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-, disulfide with L-cysteine;AMG-416 (Velcalcetide);Parsavib;S-(((S)-2-Acetamido-3-(((R)-1-(((R)-1-(((R)-1-(((R)-1-(((R)-1-(((R)-1-amino-5-guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)-L-cysteine;Etelcalcetide HCI | | CAS: | 1262780-97-1 | | MF: | C38H73N21O10S2 | | MW: | 1048.25 | | EINECS: | | | Product Categories: | | | Mol File: | 1262780-97-1.mol |  |
| | Etelcalcetide Chemical Properties |
| density | 1.58±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 2.01±0.10(Predicted) | | Sequence | H-Cys(1)-OH,Ac-D-Cys(1)-D-Ala-D-Arg-D-Arg-D-Arg-D-Ala-D-Arg-NH2(Disulfide bridge Cys1-(D-Cys1))/C(1),Ac-（D-C（1）-（D-A）-（D-R）-（D-R）-（D-R）-（D-A）-（D-R）-NH2(Disulfide bridge Cys1-(D-Cys1)) | | InChIKey | HQGWMVNIZKNABK-TZUZSESWNA-N |
| | Etelcalcetide Usage And Synthesis |
| Uses | N-Acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl- D-Argininamide-L-cysteine Disulfide is a useful research chemical used in the treatment of chronic kidney disease-mineral and bone disorder. | | Definition | ChEBI: Etelcalcetide is an oligopeptide. | | Mechanism of action | Etelcalcetide is a calcimimetic agent that allosterically modulates the
calcium-sensing receptor (CaSR). Etelcalcetide binds to the CaSR and
enhances activation of the receptor by extracellular calcium. Activation
of the CaSR on parathyroid chief cells decreases PTH secretion. | | Clinical Use | Synthetic peptide calcimimetic agent:Treatment of secondary hyperparathyroidism in
patients on haemodialysis | | Drug interactions | Potentially hazardous interactions with other drugs
Avoid with cinacalcet. | | Metabolism | Etelcalcetide is biotransformed in blood by reversible
disulphide exchange with endogenous thiols to
predominantly form conjugate with serum albumin |
| | Etelcalcetide Preparation Products And Raw materials |
|